Meletios Dimopoulos, MD, is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece. He is also the Dean of the medical school and Rector of the university.
Dr Dimopoulos obtained his medical degree from the National and Kapodistrian University of Athens School of Medicine. Prof. Dimpoulos then completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada, followed by a fellowship in hematology/oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Dimopoulos has recently received the CoMy Excellence Award and the Waldenström’s award for Myeloma Research of the International Myeloma Society.
Speaking on prognostic factors and treatment of Waldenström’s macroglobulinemia and multiple myeloma
Dr Dimopoulos’ research focuses on new treatments and prognostic factors for multiple myeloma, as well as treatments for Waldenström’s macroglobulinemia. Dr Dimopoulos was a principal investigator in a study that led to approval of lenalidomide and dexamethasone for relapsed/refractory myeloma by FDA and EMEA.